Time for Saunders to go.

Discussion in 'Allergan' started by anonymous, Dec 5, 2017 at 9:45 AM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    I have watched an amazing company being destroyed by the sheer incompetence of this CEO and his cronies. They took a well run profitable organization with a bright future and with their stupidity run it into the ground. Now in order to save themselves they will cut headcount and destroy people’s livelihood. Hey Brent, just resign and let someone with actual experience in running the business take over. In addition to that take your moronic team with you!!
     

  2. anonymous

    anonymous Guest

    This isn't a totally fair assessment. Allergan was going to be bought be Valiant through a hostile takeover and it was Allergan that approached Actavis to avoid the Valiant disaster.

    All the things that threaten Allergan currently, such as Restasis going generic and potential Botox competition hitting the US market would be things that Allergan would have faced as a stand-alone company as well. The only thing that would not have been an issue is the dead weight of Teva shares owned by Allergan currently.

    The hay-day of Allergan was going to be challenged regardless.
     
  3. anonymous

    anonymous Guest

    I agree that many of Allergans current challenges would have needed to be dealt with, but old Allergan would have done it differently. Pyott got out at the top, took the money and ran. Valeant & Ackman destroyed the company and the so called white knight BS turned out to be a spoilt brat just trying to get his seat at the Pfizer to table!
    Now he is on the ropes and the sooner the towel is thrown in the better it will be for all!

    He grabbed a well run company, removed the experienced leaders and replaced them with his yes men....they focused on buying other people's innovation and once they had it they had no idea what to do with it.

    Pfizer was BS's white knight, without them he had proved he offers little to the business world.
     
  4. anonymous

    anonymous Guest




    I would also add that the M&A that Saunders bought appears to be junk. It's one thing to have money and goals of buying technology, its another to buy good technology. Never did I think Nicholson knew what he was talking about when it came to leading the R&D group. Should have left that up to AGN and Scott Whitcup. These Actavis people are morons!
     
  5. anonymous

    anonymous Guest

    It's speculation to say that Pyott would have handled things any differently or any better. Don't forget about Pyott's flop with Semprana. That was an epic waste of money.
     
  6. anonymous

    anonymous Guest

    Yes, Semprana was a big waste of money, but was not really Pyott's fault. It made good business sense to add Semparana to Allergan's portfolio. The problem was the competence of SN and CP in R&D. They first failed to see the problem with the product in due diligence, then they were not able to fix the problem for years. If Pyott was still in charge, SN and CP would be long gone for failing to fix the problem.
     
  7. anonymous

    anonymous Guest

    And I'll throw another one out there...

    Pyott kept WAY too much cash on hand, which is a horrible mistake in this industry and one of the reasons Valient was coming with fangs and claws showing. Valient management basically said we're buying you and we're using your own money to make the first couple of loan payments. Pyott literally set the company up to be taken over.
     
  8. anonymous

    anonymous Guest


    Well of course he set the company up to be bought. He was nearing the end of his desired tenure and this was a big payday waiting to happen. Pyott knew exactly what he was doing. I think Gavin was the only guy upset in that auditorium!
     
  9. anonymous

    anonymous Guest

    I certainly hope Allergan finds another white knight soon! Stock price is unbelievably depressed. Allergan doesn't seem to be able to stop the dropping.
     
  10. anonymous

    anonymous Guest



    Keep in mind, Actavis bought AGN for $209 and cash/share. Any white knight now needs to come in well above any combo of that in order for shareholders to break even. In order to do that, AGN will need good traction in the market with demand. That won’t happen for awhile. Any acquisition by someone will need to see good phase 3 data before they dump money down on this pig.
     
  11. anonymous

    anonymous Guest

    Could see a middle eastern group scoop this up. A bunch of chic sheiks would gobble it up to gain access to all the parts needed to build their ideal model.
     
  12. anonymous

    anonymous Guest


    Go back to bed and start over warming up your pea brain.
     
  13. anonymous

    anonymous Guest

    And Saunders did what with the cash? Wasted it on M&A, doing favors for old friends.
     
  14. anonymous

    anonymous Guest



    Allergan when bought by Actavis had around $60 million laying around.
     
  15. anonymous

    anonymous Guest

    Dumb Ass!
     
  16. anonymous

    anonymous Guest

    .
     
  17. anonymous

    anonymous Guest

    Those people have a lot of CA$H MONEY and can buy us out ASAP. They already spent $450M of their CA$H on a tiny Michelangelo painting. #MakeItRain
     
  18. anonymous

    anonymous Guest


    Indian companies???

    Like who? Sun Pharmaceuticals? LOL? They are the laughing stock in the Pharma industry. These morons got no clue how to do business in the US. Me too drugs with no market share.
     
  19. anonymous

    anonymous Guest

    No Saudis, they have the ca$h!!!
     
  20. anonymous

    anonymous Guest

    Don’t forget JNJ, AMZN or GE too!!!